Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 589 | 763 | 1,027 | 1,410 | 1,359 |
| Receivables | 1 | 0 | 1 | 1 | 2 |
| TOTAL | $800 | $1,009 | $1,365 | $1,592 | $1,575 |
| Non-Current Assets | |||||
| PPE Net | 8 | 10 | 12 | 14 | 17 |
| Other Non-Current Assets | 49 | 60 | 72 | 84 | 95 |
| TOTAL | $56 | $70 | $84 | $98 | $111 |
| Total Assets | $856 | $1,079 | $1,449 | $1,690 | $1,687 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 2,943 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 1,322 | 1,370 | 1,676 | 1,785 | 1,989 |
| Accrued Expenses | 151 | 152 | 146 | 137 | 119 |
| TOTAL | $8,370 | $8,516 | $9,017 | $9,172 | $8,934 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 460 | 715 | 953 | 1,074 | 1,144 |
| Other Non-Current Liabilities | 0 | 13 | 25 | 38 | 50 |
| TOTAL | $N/A | $13 | $25 | $38 | $50 |
| Total Liabilities | $8,370 | $8,529 | $9,042 | $9,209 | $8,984 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 419,907 | 419,522 | 419,522 | 419,522 | 419,522 |
| Common Shares | 420 | 420 | 420 | 420 | 420 |
| Retained earnings | -254,041 | -253,195 | -252,690 | -252,027 | -251,251 |
| Other shareholders' equity | -48 | -50 | -48 | -14 | -13 |
| TOTAL | $-7,513 | $-7,450 | $-7,593 | $-7,519 | $-7,297 |
| Total Liabilities And Equity | $856 | $1,079 | $1,449 | $1,690 | $1,687 |